2018 American Transplant Congress
Incidence of Rejection and Antibody Formation after Immunosuppression Reduction in Patients with Biopsy Proven Polyomavirus Nephropathy
University of North Carolina, Chapel Hill, NC.
The purpose of this study is to determine the incidence of rejection and donor specific antibody (DSA) formation after immunosuppression reduction in patients with biopsy…2018 American Transplant Congress
Development of a Classification of Immunosuppressant Medication Nonadherence Tool to Enable the Objective Measurement of Immunosuppressant Medication Nonadherence in Kidney Transplant Patients
Imperial College Renal and Transplant Centre, London.
IntroductionKDIGO define nonadherence to immunosuppression as a 'deviation from the prescribed medication regimen sufficient to adversely influence the regimen's intended effect'. There is however, no…2018 American Transplant Congress
Polymorphisms of Nucleotide Factor of Activated T Cells Cytoplasmic 2 and 4 and the Risk of Acute Rejection Following Kidney Transplantation
Urology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Background: Acute rejection (AR) is a common complication of kidney transplantation. Nuclear factors of activated T cells (NFATs) are transcription factors involved in the activation…2018 American Transplant Congress
Polyclonal Cellular Immune Function is Dose-Dependently Inhibited by Immunosuppressive Drugs but Has Limited Value in Predicting Infection or Rejection Episodes
1Saarland University, Homburg/Saar, Germany; 2Saarland University, Homburg/Saar, Germany.
Background: Dosage of immunosuppressive drugs in transplant patients must be balanced to prevent graft rejection and infectious complications. Knowledge on general immune function may therefore…2018 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Department of Surgery, Duke University Medical Center, Durham, NC.
IntroductionThe field of porcine islet xenotransplantation has made significant progress in non-human primate studies in recent years. However, one major barrier preventing clinical translation of…2018 American Transplant Congress
Experience with Immunosuppressive Strategies in Vascularized Composite Allotransplantation of Face
This retrospective review of the largest face transplant cohort aims to describe the evolution of immunosuppressive (IS) regimens used in face transplant recipients.All face transplants…2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…2018 American Transplant Congress
Do We Need to Worry about EBV DNAemia in the Late Post-Transplant Period?
Background: Despite detectable Epstein-Barr virus (EBV) in blood, kidney transplant patients (KTR) may have no apparent clinical consequence. This study aims to explore the clinical…2018 American Transplant Congress
BK Viremia in Simultaneous Kidney Pancreas Recipients: Single Center Experience
Introduction: The impact of BK viremia in recipients of simultaneous pancreas and kidney transplantation (SPK) is not well known. We therefore studied the incidence and…2018 American Transplant Congress
Comparison of De Novo Rapamune versus Everolimus Maintenance Immunosuppression; an Interim Analysis
General Surgery, Ohio State University, Columbus, OH.
This is a 1 year interim analysis of the results of a 3 year, single center, randomized, prospective, open-label study comparing the efficacy and tolerability…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 138
- Next Page »